Skip to main content

The Cooper Companies stock price and financials

  • COO · Nasdaq
  • Medical devices
  • Health Care Supplies
  • S&P 500
$62.65+0.74%Close 13 Nov 2026 · Next results 3 Dec 2026
Market value
$11.91B
P/E
20.89
EV / EBITDA
15.41
Beta · 1 year
0.48
Return · 1 year
−13.6%
52-week range$51.01 — $89.83

Share price close 16 Nov 2026

+9.4%1 monthHigh $64.42Low $57.94
$56$58$60$62$64$6623 Oct29 Oct4 Nov10 Nov16 Nov
+5.3%6 monthsHigh $76.82Low $53.27
$50$60$70$80Q2 FY2026 report filed 5 Jun 2026Q3 FY2026 report filed 9 Sep 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
−23.4%year to dateHigh $84.32Low $53.27
$50$60$70$80$90Q1 FY2026 report filed 6 Mar 2026Q2 FY2026 report filed 5 Jun 2026Q3 FY2026 report filed 9 Sep 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
−12.9%1 yearHigh $84.32Low $53.27
$50$60$70$80$90Q4 FY2025 report filed 5 Dec 2025Q1 FY2026 report filed 6 Mar 2026Q2 FY2026 report filed 5 Jun 2026Q3 FY2026 report filed 9 Sep 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
−26.5%3 yearsHigh $111.23Low $53.27
$40$60$80$100$120Q4 FY2023 report filed 8 Dec 2023Q1 FY2024 report filed 1 Mar 2024Q2 FY2024 report filed 31 May 2024Q3 FY2024 report filed 29 Aug 2024Q4 FY2024 report filed 6 Dec 2024Q1 FY2025 report filed 7 Mar 2025Q2 FY2025 report filed 30 May 2025Q3 FY2025 report filed 28 Aug 2025Q4 FY2025 report filed 5 Dec 2025Q1 FY2026 report filed 6 Mar 2026Q2 FY2026 report filed 5 Jun 2026Q3 FY2026 report filed 9 Sep 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+46.0%10 yearsHigh $113.98Low $40.53
$40$60$80$100$120Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

The Cooper Companies reported revenue of $4.09 billion for fiscal year 2025 (the twelve months to 31 Oct 2025), up 5.1% from fiscal 2024. Net income was $375 million and diluted earnings per share $1.87.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 31 Jul 2026), revenue was $1.07 billion, up 0.6% from a year earlier.

Figures from The Cooper Companies's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 9 Sep 2026.

Against Health Care

Growth
Upper half
Revenue +11.0% a year over five years · 11th of 37
Profitability
Bottom quarter
Return on invested capital 4.3%, five-year average · 34th of 38
Balance sheet
Lower half
Net debt 2.6× EBITDA · 26th of 38
Valuation
Cheaper than most
P/E 20.9 · 9th of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$4.09B+5.1%
Net income
$374.9M−4.4%
Diluted EPS
$1.87−4.6%
Gross margin
65.5%−1.1 pts
Free cash flow
$433.7M+50.5%
Net debt
$2.67B−2.6%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$1B$2B$3B$4B$5BRevenue, FY16: $1.97BNet income, FY16: $273.9MFY16Revenue, FY17: $2.14BNet income, FY17: $372.9MFY17Revenue, FY18: $2.53BNet income, FY18: $139.9MFY18Revenue, FY19: $2.65BNet income, FY19: $466.7MFY19Revenue, FY20: $2.43BNet income, FY20: $238.4MFY20Revenue, FY21: $2.92BNet income, FY21: $2.94BFY21Revenue, FY22: $3.31BNet income, FY22: $385.8MFY22Revenue, FY23: $3.59BNet income, FY23: $294.2MFY23Revenue, FY24: $3.9BNet income, FY24: $392.3MFY24Revenue, FY25: $4.09BNet income, FY25: $374.9MFY25

Latest quarter · Q3 FY2026 to 31 Jul 2026, filed 9 Sep 2026 · Full results →

Revenue
$1.07B+0.6% on a year
Gross margin
66.8%+1.5 pts on a year
Operating income
$222.0M+26.4% on a year
Net income
$432.8M+340% on a year
Diluted EPS
$2.24+357% on a year
Free cash flow
$273.0M+66.0% on a year

Comparable companies All of Health Care →

The Cooper Companies beside the other S&P 500 members in Health Care Supplies, then the largest in Health Care, by market value.

The Cooper Companies and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
The Cooper CompaniesCOO$11.91B+0.7%−13.6%+4.7%13.5%20.9
Align TechnologyALGN$11.84B+0.8%+18.8%+4.4%11.8%24.1
West Pharmaceutical ServicesWST—+1.2%+52.1%———
Eli LillyLLY$1.37T+1.1%+41.8%+45.5%31.9%49.6
Johnson & JohnsonJNJ$686.1B+0.8%+47.0%+7.8%16.2%42.6
AbbVieABBV$525.9B+0.2%+26.5%+10.7%15.7%51.1
AmgenAMGN$253.8B−0.3%+38.5%+8.2%24.1%27.0

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%50%100%150%65.5%16.7%9.2%FY16FY19FY22FY25

The Cooper Companies revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

The Cooper Companies revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Coopervision Segment$2.15B$2.24B+4.2%$2.42B+8.0%$2.61B+7.7%$2.74B+5.2%
CooperSurgical$770.5M$1.07B+38.2%$1.17B+9.8%$1.29B+10.0%$1.35B+4.9%
Total revenue$2.92B$3.31B$3.59B$3.90B$4.09B

By region

The Cooper Companies revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$1.34B$1.64B+22.3%$1.81B+10.6%$1.97B+8.5%$2.05B+4.5%
Europe$957.9M$987.2M+3.1%$1.04B+5.5%$1.16B+11.0%$1.25B+8.4%
Rest of world$625.4M$682.7M+9.2%$739.8M+8.4%$773.6M+4.6%$785.2M+1.5%
Total revenue$2.92B$3.31B$3.59B$3.90B$4.09B

Financial statements

Fiscal years, the latest ending 31 Oct 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

The Cooper Companies income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$1.97B$2.14B$2.53B$2.65B$2.43B$2.92B$3.31B$3.59B$3.90B$4.09B
Revenue growth+9.4%+8.8%+18.4%+4.8%−8.4%+20.2%+13.2%+8.6%+8.4%+5.1%
Gross profit$1.17B$1.37B$1.63B$1.76B$1.53B$1.96B$2.14B$2.36B$2.60B$2.68B
Operating income$324.1M$429.1M$403.1M$546.7M$311.8M$505.8M$507.6M$533.1M$705.7M$682.9M
Net income$273.9M$372.9M$139.9M$466.7M$238.4M$2.94B$385.8M$294.2M$392.3M$374.9M
Diluted EPS$1.40$1.88$0.70$2.33$1.20$14.78$1.94$1.48$1.96$1.87
Gross margin59.6%63.9%64.4%66.2%63.1%66.9%64.7%65.6%66.6%65.5%
Operating margin16.5%20.1%15.9%20.6%12.8%17.3%15.3%14.8%18.1%16.7%
Net margin13.9%17.4%5.5%17.6%9.8%101%11.7%8.2%10.1%9.2%

Cash flow

The Cooper Companies cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$509.6M$593.6M$668.9M$713.2M$486.6M$738.6M$692.4M$607.5M$709.3M$796.1M
Capital expenditure$152.6M$127.2M$193.6M$292.1M$310.4M$214.4M$242.0M$392.5M$421.2M$362.4M
Free cash flow$357.0M$466.4M$475.3M$421.1M$176.2M$524.2M$450.4M$215.0M$288.1M$433.7M

Balance sheet and shares

The Cooper Companies balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$100.8M$88.80M$77.70M$89.00M$115.9M$95.90M$138.2M$120.8M$107.6M$110.6M
Total debt$1.54B$1.17B$2.02B$1.83B$2.06B$1.75B$3.00B$2.82B$2.85B$2.78B
Shareholders' equity$2.70B$3.18B$3.31B$3.63B$3.82B$6.94B$7.17B$7.55B$8.08B$8.24B
Diluted shares196M198M199M200M198M199M199M199M200M200M
Dividends per share$0.01$0.01$0.01$0.03$0.03$0.03$0.01$0.04——

Quarterly figures

The last eight fiscal quarters, the latest ending 31 Jul 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

The Cooper Companies quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$1.02B$964.7M$1.00B$1.06B$1.07B$1.02B$1.08B$1.07B
Revenue, year on year+9.8%+3.6%+6.3%+5.7%+4.6%+6.2%+7.9%+0.6%
Gross margin66.5%68.4%67.8%65.3%61.1%67.9%68.0%66.8%
Operating income$198.4M$182.0M$184.8M$175.7M$140.4M$212.8M−$31.00M$222.0M
Net income$117.5M$104.3M$87.70M$98.30M$84.60M$130.8M−$77.90M$432.8M
Diluted EPS$0.59$0.52$0.44$0.49$0.43$0.66−$0.40$2.24
Free cash flow$128.1M$101.2M$18.10M$164.5M$149.9M$158.7M$96.40M$273.0M

Operating KPIs

The operating figures The Cooper Companies reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

The Cooper Companies operating KPIs
KPILatestPeriodChange on a yearRecent periods
Toric and multifocal revenue$363.8Mquarter to 31 Jul 2026up 1.4%
Sphere, other revenue$353.2Mquarter to 31 Jul 2026down 1.8%
Office and surgical revenue$208.0Mquarter to 31 Jul 2026up 1.6%
Fertility revenue$141.2Mquarter to 31 Jul 2026up 3.0%
Coopervision Segment revenue$717.0Mquarter to 31 Jul 2026down 0.2%
CooperVision revenue$717.0Mquarter to 31 Jul 2026down 0.2%
Coopersurgical Segment revenue$349.2Mquarter to 31 Jul 2026up 2.1%
CooperSurgical revenue$349.2Mquarter to 31 Jul 2026up 2.1%
United States revenue$519.5Mquarter to 31 Jul 2026up 0.6%
Europe revenue$357.5Mquarter to 31 Jul 2026up 4.2%
Rest of world revenue$189.2Mquarter to 31 Jul 2026down 5.9%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was The Cooper Companies's revenue in fiscal 2025?

$4.09 billion for fiscal year 2025 (the twelve months to 31 Oct 2025), as reported in its annual report.

What was The Cooper Companies's net income in fiscal 2025?

$375 million for fiscal year 2025 (the twelve months to 31 Oct 2025).

What were The Cooper Companies's diluted earnings per share in fiscal 2025?

$1.87 for fiscal year 2025 (the twelve months to 31 Oct 2025).

What is The Cooper Companies's gross margin?

65.5% for fiscal year 2025 (the twelve months to 31 Oct 2025): gross profit divided by revenue.

What is The Cooper Companies's operating margin?

16.7% for fiscal year 2025 (the twelve months to 31 Oct 2025): operating income divided by revenue.

How much free cash flow did The Cooper Companies generate in fiscal 2025?

$434 million for fiscal year 2025 (the twelve months to 31 Oct 2025): operating cash flow less capital expenditure.

Where does The Cooper Companies's revenue come from?

In fiscal 2025, by segment: Coopervision Segment $2.74B (67%), CooperSurgical $1.35B (33%), out of $4.09B in all, as stated in its annual report.

In the terminal

Twenty years of The Cooper Companies's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans